LTGO · Why this verdict
Why Latigo Biotherapeutics (LTGO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Latigo is a cash-burning speculative biotech with quality at 1.4, a Piotroski score of 0 of 9 and deeply negative momentum, partly offset by $5.04M of insider buying; the headline 227% analyst upside rests on a target the engine rejected as implausible.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality of 1.4 is below the 4.0 floor, with a Piotroski F-Score of 0 of 9, an operating margin of -49.5% and negative free cash flow. Warnings | Quality stays below 4.0 until clinical progress translates into revenue or reduced burn over 12 months. | ↑Improving |
| CounterStandard quality metrics penalize pre-revenue biotechs structurally, and a current ratio score of 4.4 suggests some liquidity cushion. | ||
The latest quarter EPS of -$27.59 missed the -$0.66 estimate by a wide margin, reflecting very large losses relative to expectations. Earnings | Quarterly EPS loss narrows to less than $1.00 per share by the following quarters. | ↑Improving |
| CounterA loss this large against a small estimate may reflect one-time items, so the single data point may overstate the ongoing burn rate. | ||
Insiders bought $5,040,000 (0.475% of market cap) in 2 purchases over 90 days with no sales. Insider breakdown | Insider net buying stays positive with no open-market selling over 12 months. | →Stable |
| CounterThe amount is under 0.5% of market cap, and insider buying does not protect against binary clinical outcomes. | ||
Momentum of 1.5 fails the engine's 4.5 minimum, with RSI at 27, price below the 200-day average and falling on-balance volume. Engine gate (failed) | Momentum recovers above 4.5 before any position is justified. | →Stable |
| CounterAn RSI of 27 is deeply oversold and can precede a sharp rebound, especially with insiders buying. | ||
The raw analyst target of $52.25 against a price of $16.00 (ratio 3.3x) was rejected as implausible, so the reported 227% analyst upside should not be relied on. Bear case | The target-to-price ratio normalizes below 2x as analysts revise. | ↑Improving |
| CounterBiotech targets are often set on probability-weighted pipeline values far above the price, so a large gap is not necessarily an error. | ||
Quality of 1.4 is below the 4.0 floor, with a Piotroski F-Score of 0 of 9, an operating margin of -49.5% and negative free cash flow.
↑ImprovingWarnings
- Expectation
- Quality stays below 4.0 until clinical progress translates into revenue or reduced burn over 12 months.
CounterStandard quality metrics penalize pre-revenue biotechs structurally, and a current ratio score of 4.4 suggests some liquidity cushion.
The latest quarter EPS of -$27.59 missed the -$0.66 estimate by a wide margin, reflecting very large losses relative to expectations.
↑ImprovingEarnings
- Expectation
- Quarterly EPS loss narrows to less than $1.00 per share by the following quarters.
CounterA loss this large against a small estimate may reflect one-time items, so the single data point may overstate the ongoing burn rate.
Insiders bought $5,040,000 (0.475% of market cap) in 2 purchases over 90 days with no sales.
→StableInsider breakdown
- Expectation
- Insider net buying stays positive with no open-market selling over 12 months.
CounterThe amount is under 0.5% of market cap, and insider buying does not protect against binary clinical outcomes.
Momentum of 1.5 fails the engine's 4.5 minimum, with RSI at 27, price below the 200-day average and falling on-balance volume.
→StableEngine gate (failed)
- Expectation
- Momentum recovers above 4.5 before any position is justified.
CounterAn RSI of 27 is deeply oversold and can precede a sharp rebound, especially with insiders buying.
The raw analyst target of $52.25 against a price of $16.00 (ratio 3.3x) was rejected as implausible, so the reported 227% analyst upside should not be relied on.
↑ImprovingBear case
- Expectation
- The target-to-price ratio normalizes below 2x as analysts revise.
CounterBiotech targets are often set on probability-weighted pipeline values far above the price, so a large gap is not necessarily an error.
Per-dimension breakdown
Quality
1.4/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 4.4 |
| Moat | 4.0 |
| Piotroski F | 0.0 |
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 0/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 5.5 |
| Volume | 1.6 |
- ▸Volume accumulation (rising OBV)
Sentiment
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.0 |
| Analyst rating | 7.1 |
| Price target | 10.0 |
- ▸Light analyst coverage (4.0) — signal dampened
- ▸Analyst upside: 230%
Insider
8.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 8.0 |
| insider conviction | 8.0 |
- ▸Notable insider buying — $5,040,000 (0.480% of mkt cap)
Peer rank
3.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.0 |
| support resistance | 4.4 |
| 52w position | 2.2 |
Risk (lower is worse)
4.1/10data confidence 80%| Component | Sub-score |
|---|---|
| days to cover | 9.0 |
| volatility | 0.0 |
| debt equity | 2.5 |
| news risk | 5.0 |
Catalyst
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 7.0 |
- ▸Earnings in 14 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:6.3>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- EARNINGS_PROXIMITY:14d<=14d (soft)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 55 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Insider at 8.0 and asymmetric R:R of 0.00.
The strongest dimensions are Insider at 8.0, Sentiment at 7.3, and Momentum at 6.3; the weakest are Quality at 1.4, Catalyst at 3.0, and Technical at 3.5. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Minimum Floor
Trip ifQuality score rises above 4.0 from current 1.4 for 2 consecutive quarters.
- P2Notable Insider Buying
Trip ifInsider net selling exceeds $1M in any 90-day window.
- P3Large Earnings Miss
Trip ifQuarterly EPS loss stays above $5.00 per share for 2 consecutive quarters.
- P4Capitulation Level Momentum
Trip ifMomentum score rises above 4.5 from current 1.5.
- P5Implausible Analyst Target
Trip ifRaw analyst target to price ratio falls below 2x from current 3.3x.